Role of Neuropilin 1 in COVID-19 Patients with Acute Ischemic Stroke

Al-Thomali, Asma W.; Al-Kuraishy, Hayder M; Al-Gareeb, Ali I; Al-Buhadiliy, Ali Kadhem; Waard, Michel De; Sabatier, Jean‐Marc; Khalil, Atif Ali Khan; Saad, Hebatallah M.; Batiha, Gaber El‐Saber

doi:10.3390/biomedicines10082032

Cited by 35 publications

(26 citation statements)

References 143 publications

(176 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Statins are one of the main cornerstone drugs for the management of cardiovascular disorders, regardless of dyslipidemia status via their pleiotropic effects. The increasing use of statins, mainly in the elderly groups for primary and secondary preventions of cardiovascular diseases, makes them a commonly used medication globally [ 32 , 33 , 48 ]. It has been shown that 30% of people in the USA over the age of 40 are on statins [ 32 , 33 , 35 ].…”

Section: Statins and Admentioning

confidence: 99%

Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review

et al. 2022

View full text Add to dashboard Cite

Alzheimer’s disease (AD) was used to describe pre-senile dementia to differentiate it from senile dementia, which develops in the adult age group of more than 65 years. AD is characterized by the deposition of amyloid beta (Aβ) plaque and tau-neurofibrillary tangles (TNTs) in the brain. The neuropathological changes in AD are related to the deposition of amyloid plaques, neurofibrillary tangles, and progression of neuroinflammation, neuronal mitochondrial dysfunction, autophagy dysfunction, and cholinergic synaptic dysfunction. Statins are one of the main cornerstone drugs for the management of cardiovascular disorders regardless of dyslipidemia status. Increasing the use of statins, mainly in the elderly groups for primary and secondary prevention of cardiovascular diseases, may affect their cognitive functions. Extensive and prolonged use of statins may affect cognitive functions in healthy subjects and dementia patients. Statins-induced cognitive impairments in both patients and health providers had been reported according to the post-marketing survey. This survey depends mainly on sporadic cases, and no cognitive measures were used. Evidence from prospective and observational studies gives no robust conclusion regarding the beneficial or detrimental effects of statins on cognitive functions in AD patients. Therefore, this study is a narrative review aimed with evidences to the beneficial, detrimental, and neutral effects of statins on AD.

show abstract

Section: Statins and Admentioning

confidence: 99%

Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Thus, female sex is regarded as a potential risk factor for the development of PSC due to higher immunological response and hormonal changes [ 48 ]. However, some studies found no gender difference in the risk of developing PCS after an acute SARS-CoV-2 infection [ 49 , 50 ]. Furthermore, co-morbidities, advanced age, and the severity of the initial disease are associated with an increased risk of developing PCS [ 51 ].…”

Section: Introductionmentioning

confidence: 99%

Pathophysiology of Post-COVID syndromes: a new perspective

Batiha

Al-Kuraishy

Al-Gareeb

et al. 2022

Virol J

Self Cite

View full text Add to dashboard Cite

Most COVID-19 patients recovered with low mortality; however, some patients experienced long-term symptoms described as “long-COVID” or “Post-COVID syndrome” (PCS). Patients may have persisting symptoms for weeks after acute SARS-CoV-2 infection, including dyspnea, fatigue, myalgia, insomnia, cognitive and olfactory disorders. These symptoms may last for months in some patients. PCS may progress in association with the development of mast cell activation syndrome (MCAS), which is a distinct kind of mast cell activation disorder, characterized by hyper-activation of mast cells with inappropriate and excessive release of chemical mediators. COVID-19 survivors, mainly women, and patients with persistent severe fatigue for 10 weeks after recovery with a history of neuropsychiatric disorders are more prone to develop PCS. High D-dimer levels and blood urea nitrogen were observed to be risk factors associated with pulmonary dysfunction in COVID-19 survivors 3 months post-hospital discharge with the development of PCS. PCS has systemic manifestations that resolve with time with no further complications. However, the final outcomes of PCS are chiefly unknown. Persistence of inflammatory reactions, autoimmune mimicry, and reactivation of pathogens together with host microbiome alterations may contribute to the development of PCS. The deregulated release of inflammatory mediators in MCAS produces extraordinary symptoms in patients with PCS. The development of MCAS during the course of SARS-CoV-2 infection is correlated to COVID-19 severity and the development of PCS. Therefore, MCAS is treated by antihistamines, inhibition of synthesis of mediators, inhibition of mediator release, and inhibition of degranulation of mast cells.

show abstract

“…Reactive oxygen species play crucial roles in cancer initiation, and progression and elevated levels were observed in malignant cells compared with their regular counterparts [ 26 , 27 ]. Several anti-oxidative compounds have been shown to protect against experimental carcinogenesis and induce the apoptosis of cancer cells [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Phytochemical Analysis and Understanding the Antioxidant and Anticancer Properties of Methanol Extract from Litsea glutinosa: In Vitro and In Vivo Studies

et al. 2022

View full text Add to dashboard Cite

Litsea glutinosa (L. glutinosa) is considered an evidence-based medicinal plant for the treatment of cancer, the leading cause of death worldwide. In our study, the in vitro antioxidant and in vivo anticancer properties of an essential ethno-medicinal plant, L. glutinosa, were examined using non-toxic doses and a phytochemical analysis was executed using gas-chromatography–mass-spectrometry. The in vitro antioxidant study of the L. glutinosa methanolic extract (LGBME) revealed a concentration-dependent antioxidant property. The bark extract showed promising antioxidant effects in the 2,2-diphenyl-1-picryl-hydrazyl (DPPH) assay. The strongest antioxidant activity was demonstrated at the maximum concentration (50 µg/mL). The IC50 values of the LGBME and BHT were 5.51 and 5.01 µg/mL, respectively. At the same concentration, the total antioxidant capacity of the LGBME was 0.161 µg/mL and the ferric reducing antioxidant power assay result of the LGBME was 1.783 µg/mL. In the cytotoxicity study, the LD50 of the LGBME and gallic acid were 24.93 µg/mL and 7.23 µg/mL, respectively. In the in vivo anticancer-activity studies, the LGBME, particularly at a dose of 150 mg/kg/bw, showed significant cell-growth inhibition, decreased tumor weight, increased mean survival rate, and upregulated the reduced hematological parameters in EAC (Ehrlich’s ascites carcinoma)-induced Swiss albino mice. The highest cell-growth inhibition, 85.76%, was observed with the dose of 150 mg/kg/bw. Furthermore, the upregulation of pro-apoptotic genes (p53, Bax) and the downregulation of anti-apoptotic Bcl-2 were observed. In conclusion, LGBME extract has several bioactive phytoconstituents, which confirms the antioxidant and anticancer properties of L. glutinosa.

show abstract

Role of Neuropilin 1 in COVID-19 Patients with Acute Ischemic Stroke

Cited by 35 publications

References 143 publications

Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review

Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review

Pathophysiology of Post-COVID syndromes: a new perspective

Phytochemical Analysis and Understanding the Antioxidant and Anticancer Properties of Methanol Extract from Litsea glutinosa: In Vitro and In Vivo Studies

Contact Info

Product

Resources

About